# What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained > What is tirzepatide? A 39-amino-acid synthetic peptide that activates both GIP and GLP-1 receptors — FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea. Structure, mechanism, and regulatory history explained. ## The short version Tirzepatide is a medicine your doctor can prescribe. It is a synthetic peptide — a short string of amino acids, the building blocks of proteins — that mimics two hormones your gut releases after meals: GIP and GLP-1. These hormones signal the pancreas to release insulin when blood sugar rises, suppress the glucagon that raises blood sugar between meals, slow digestion so you feel full longer, and reduce appetite signals to the brain. Tirzepatide activates both of these receptor systems with a single weekly injection. The FDA approved it for type 2 diabetes in May 2022, for chronic weight management in November 2023, and later for moderate-to-severe obstructive sleep apnea in people with obesity. In clinical trials it produced larger reductions in blood sugar and body weight than most previously approved treatments in these conditions. This page explains the molecular structure, how the mechanism works, and how the compound came to be approved. ## What is tirzepatide — molecular identity and structure Tirzepatide (INN: tirzepatide; development code LY3298176; CAS 2023788-19-2; molecular formula C₂₂₅H₃₄₈N₄₈O₆₈; molecular weight 4,813.53 Da; ATC code A10BX16) is a linear synthetic peptide of 39 amino acids engineered from the native GIP hormone sequence. Its defining structural feature is a C20 fatty diacid arm — eicosanedioic acid — attached via a glutamic acid linker and two (2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) spacer units to a lysine side chain at position 20. This fatty diacid moiety confers high albumin-binding affinity and substantially extends circulating half-life compared with unmodified peptides, achieving an elimination half-life of approximately five days and enabling once-weekly subcutaneous dosing [10]. The peptide backbone carries sequence modifications that enable engagement with the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously. This dual engagement — activating both receptors with a single molecule — distinguishes tirzepatide from the prior class of selective GLP-1 receptor agonists and is the pharmacological basis for its designation as the first approved dual incretin agonist [7, 8]. ## Tirzepatide mechanism of action — how dual receptor engagement works The two incretin hormones (hormones released from the gut after eating that amplify insulin release) tirzepatide mimics are GIP and GLP-1. Both are secreted by intestinal cells in response to nutrient absorption and signal to pancreatic beta cells — the cells that produce insulin — to increase insulin output in proportion to blood-glucose concentration. This mechanism is called glucose-dependent insulinotropic activity, meaning insulin release is amplified only when glucose is present, which limits hypoglycaemia risk at therapeutic doses. In vitro receptor and signalling studies established that tirzepatide is an imbalanced and biased dual agonist [5]. 'Imbalanced' means it engages the GIPR more fully than the GLP-1R. 'Biased' refers to its selective activation of the cAMP signalling pathway at the GLP-1R, with weaker beta-arrestin recruitment and receptor internalisation than native GLP-1 produces; this biased profile is proposed to enhance insulin secretion from pancreatic islets. Beyond insulin secretion, coordinated GIP and GLP-1 receptor agonism also: suppresses glucagon secretion in a glucose-dependent manner, transiently slows gastric emptying (reducing postprandial glucose spikes), and produces central appetite suppression that reduces food intake and drives body weight reduction [1, 5]. The net clinical result across the phase 3 programme was larger glycaemic and weight reductions than selective GLP-1 receptor agonism alone — the pharmacological hypothesis that motivated developing the dual-agonist approach validated in humans [1, 2, 3]. ## Regulatory history — from discovery to three FDA approvals LY3298176, the development code for tirzepatide, was first reported in the peer-reviewed literature in 2018 [1]. The discovery paper described the fatty-acid-modified dual GIP/GLP-1 agonist design, in vitro characterisation showing activation of both receptor systems, superior body weight and food intake reduction versus a selective GLP-1 receptor agonist in mice, and a Phase 1 programme in 142 human subjects (healthy volunteers plus a T2D cohort) that confirmed the pharmacokinetics supporting once-weekly dosing. The phase 3 clinical development then split into two parallel programmes: SURPASS (five trials in type 2 diabetes) and SURMOUNT (four trials in obesity and overweight). The U.S. FDA approved tirzepatide for type 2 diabetes in May 2022, based principally on the SURPASS programme showing superior HbA1c reduction versus multiple comparators [7]. The obesity approval followed in November 2023, after SURMOUNT-1 demonstrated mean weight reductions of up to -20.9% at the 15 mg dose over 72 weeks — the largest weight reduction in any large randomised controlled trial for chronic weight management [3]. An additional approval for moderate-to-severe obstructive sleep apnea in adults with obesity followed, supported by SURMOUNT-OSA. The 2026 American College of Physicians living clinical guideline placed semaglutide and tirzepatide as conditional first-line pharmacological recommendations for obesity and for overweight plus a comorbidity [11]. For the detailed efficacy and safety evidence from these trials, see [Tirzepatide research](/research). For what participants have reported in real-world settings, see [Tirzepatide effects](/effects). --- An independent regulatory reading desk — the tirzepatide approval and trial record, cited to source, with no clinical role held.